Amsterdam, June 5, 2009 – AIMM Therapeutics B.V. (AIMM) and the Life Sciences Fund
Amsterdam B.V. announced today the closure of AIMM’s financing round.
AIMM is a biotech company spun-out of the Netherlands Cancer Institute and the Academic
Medical Center at the University of Amsterdam. The company aims to develop high quality
human monoclonal antibodies to treat diseases with a high, unmet medical need. AIMM exploits
and develops new, innovative technologies to generate stable monoclonal cell lines of human
antibody-producing B cells against infectious agents.
AIMM’s first product is an antibody against Respiratory Syncytial Virus (RSV), a virulent easily
transmissible virus and the most common cause of lower respiratory tract disease in children
younger than two years old. The immune system of these young infants is often compromised and
therefore administration of anti-RSV antibodies is necessary to confer protection against this
virus. In addition, AIMM has developed human antibodies against one other viral disease and one
Dr. Willem van Oort, CEO at AIMM: “We very pleased with the closure of this financing round.
The funding from the Life Sciences Fund Amsterdam will enable us to further develop our
proprietary technology platform and to develop new antibodies against any viral and bacterial
“I am very excited to be making this investment in AIMM” says Tom Schwarz, partner at the Life
Sciences Fund Amsterdam. “The results of the RSV antibody-tests proof the uniqueness of the
anti-body platform developed by AIMM’s Chief Scientific Officer, Professor Hergen Spits. I am
looking forward to working closely with the management team as a new member of the
company’s Supervisory Board.”
About AIMM Therapeutics (www.aimmtherapeutics.com)
AIMM therapeutics B.V. is a biotech company established in 2004 with the goal to develop
therapeutic human monoclonal antibodies. AIMM is located at the premises of the Academic
Medical Center (AMC) of the University of Amsterdam. It capitalizes on a technology to
immortalize human B cells enabling isolation of cloned cell lines that produce antibodies of high
clinical value. This technology has been developed in the laboratory of Professor Spits while he
was working at the Netherlands Cancer Institute (NKI) and subsequently at the AMC.
About the Life Sciences Fund Amsterdam (www.biomedcluster.nl/lsfa)
The Life Sciences Fund Amsterdam B.V. is an independent venture capital fund focusing on early
stage companies and (university) spin-outs in the biotechnology and biomedical field with a
presence in the Amsterdam region. The fund targets companies that are developing commercially
promising products and technologies in life sciences, including pharmaceuticals, biotechnology,
information technology and other high technology opportunities that offer venture capital returns.